A Phase 4 interventional study of Measles-Rubella (MR) Vaccine in Safety Issues and Immunogenicity, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to participants aged 9 Months to 47 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by PT Bio Farma · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants
PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
Biological: Measles-Rubella (MR) Vaccine
open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
Biological: Measles-Rubella (MR) Vaccine
Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
Number of Immediate systemic events
Number of subjects with at least one serious immediate systemic events within 30 minutes after vaccination
Time frame: 30 minutes
Percentage of immediate systemic events
Percentage of subjects with at least one serious immediate systemic events within 30 minutes after vaccination
Time frame: 30 minutes
Local reaction
Number of subjects with at least one local reaction occurring within 72 h after vaccination.
Time frame: 72 hours
Systemic reaction
Number of subjects with at least one systemic event occurring within 72 h after vaccination.
Time frame: 72 hours
Delayed Local reaction
Number of subjects with at least one local reaction occurring between day 4-14 after vaccination.
Time frame: 11 days
Delayed systemic event
Number of subjects with at least one systemic event occurring between day 4-14 after vaccination.
Time frame: 11 days
Late Local reaction
-Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.
Time frame: 14 days
Late Safety (Systemic event)
Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.
Time frame: 14 days
Safety (serious adverse event)
- Number of serious adverse event occuring from inclusion until 28 days after immunization
Time frame: 28 days
Immunogenicity for Measles (subject with anti measles titer ≥ 8 (1/dil))
- Percentage of subjects with anti measles titer ≥ 8 (1/dil), 28 days after one dose of MR vaccine in Infants \& Children.
Time frame: 28 days
Immunogenicity for Measles (Geometric Mean Titer)
- Geometric Mean Titer of measles antibody
Time frame: 28 days
Immunogenicity for Measles (increasing measles antibody titer ≥ 4 times)
- Percentage of infants with increasing measles antibody titer ≥ 4 times
Time frame: 28 days
Immunogenicity for Measles (seroconversion from seronegative to seropositive)
- Percentage of infants with transition of seronegative to seropositive.
Time frame: 28 days
Immunogenicity for Rubella (Subjects with anti rubella titer ≥11 IU/ml)
- Percentage of subjects with anti rubella titer ≥11 IU/ml, 28 days after one dose of MR vaccine in Infants \& Children.
Time frame: 28 days
Immunogenicity for Rubella (Geometric Mean Titer)
- Geometric Mean Titer of Rubella antibody.
Time frame: 28 days
Immunogenicity for Rubella (increasing rubella antibody titer ≥ 4 times)
- Percentage of infants with increasing rubella antibody titer ≥ 4 times
Time frame: 28 days
Immunogenicity for Rubella (seroconversion from seronegative to seropositive)
- Percentage of infants with transition of seronegative to seropositive.
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Feb 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.